XML 51 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other (Income)/Deductions - Net Other (Income)/Deductions - Net (Tables)
 12 Months Ended
Dec. 31, 2018
Other Income and Expenses [Abstract]  
Components of Other (Income)/Deductions—Net
The components of Other (income)/deductions—net follow:
 
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

Royalty-related income(a)
 
$
(28
)
 
$
(12
)
 
$
(30
)
Interest income
 
(31
)
 
(13
)
 
(8
)
Identifiable intangible asset impairment charges
 
—

 
—

 
1

Net (gain)/loss on sale of assets(b)
 
(40
)
 
11

 
(26
)
Certain legal and other matters, net(c)
 
—

 
(8
)
 
14

Foreign currency loss(d)
 
31

 
29

 
49

Other, net(e)
 
(15
)
 
(1
)
 
(2
)
Other (income)/deductions—net
 
$
(83
)
 
$
6

 
$
(2
)
(a) 
For 2017, includes an adjustment to our royalty income.
(b) 
For 2018, represents a gain on the divestiture of certain agribusiness products within our International segment, and a net loss related to sales of certain manufacturing sites and products as part of our supply network strategy initiative. For 2017, primarily represents a net loss related to sales of certain manufacturing sites and products, including our manufacturing site in Guarulhos, Brazil, as part of our operational efficiency initiative and supply network strategy. For 2016, represents a net gain on the sale of certain manufacturing sites and products, partially offset by the loss on the sale of our share of our Taiwan joint venture, as part of our operational efficiency initiative.
(c) 
In July 2014 and December 2016, we reached commercial settlements with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. For 2017, includes income associated with an insurance recovery related to these commercial settlements, as well as a favorable outcome on a patent infringement settlement. For 2016, represents a charge related to the commercial settlement in Mexico for these products.
(d) 
Primarily driven by costs related to hedging and exposures to certain emerging market currencies. For 2016, also includes losses related to the depreciation of the Egyptian pound in the fourth quarter of 2016.
(e) 
For 2018, primarily includes a net gain related to the relocation of a manufacturing site in China.